Aviko Radiopharmaceuticals

What Aviko Radiopharmaceuticals does

Aviko Radiopharmaceuticals is a development-stage biotechnology company founded in 2021 by Deerfield Management to advance Boron Neutron Capture Therapy (BNCT) for treating solid tumors with high unmet clinical need, particularly head and neck and brain cancers. The company is developing a pipeline of novel boron medicines administered intravenously that preferentially accumulate in tumor cells; when irradiated at the tumor site with safe, low-energy neutrons, the boron releases alpha particles that selectively destroy cancer cells while sparing healthy tissue. Aviko operates as part of an integrated three-party BNCT ecosystem, pairing its boron compounds with Neutron Therapeutics' nuBeam accelerator-based neutron delivery system and Leo Cancer Care's upright patient positioning platform to deliver a complete BNCT treatment solution.

Aviko's products have not received FDA or any other regulatory authorization and are not commercially available. The company is headquartered at 345 Park Avenue South, New York, at Cure., a healthcare innovation campus, and is supported operationally by Deerfield Discovery and Development (3DC), which provides integrated drug development capabilities from early-stage discovery through pre-clinical testing and clinical trials. The Deerfield External Operations team provides additional financial and business development support. Leadership is drawn primarily from the Deerfield ecosystem: CEO Dave Greenwald concurrently serves as vice president of business development at Deerfield Management, and CMO Holly Schachner is also CMO of Deerfield 3DC.

Aviko pursues a partnership-led go-to-market model, building relationships with academic medical centers, biopharmaceutical companies, and healthcare investors to establish BNCT treatment facilities in the United States. There are currently no BNCT treatment centers in the U.S., and Aviko is working to build the first, against a backdrop of approximately 33 BNCT centers globally with 21 hospital-based (Japan leads with 10, China with 5). The intended revenue model centers on pharmaceutical sales of boron medicines to BNCT treatment centers post-approval, with supplemental potential licensing and partnership income; pricing has not been disclosed and the company is pre-revenue.

Name

Aviko Radiopharmaceuticals

Legal name

Aviko Radiopharmaceuticals, LLC

Website

https://avikobnct.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Aviko Radiopharmaceuticals is a development-stage biotech developing boron medicines for Boron Neutron Capture Therapy (BNCT), a precision oncology modality for solid tumors. Founded in 2021 by Deerfield Management, the company partners to establish the first U.S. BNCT treatment centers.

Ownership category

akta.pro rank

Product category

Radiopharmaceutical Oncology

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Boron neutron capture therapy
• Radiopharmaceutical medicines
• Oncology drug development
• Cancer precision medicine
• Biopharmaceutical pipeline

Headquarters

HQ city

New York

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical/Biologic Sales: Aviko is developing a pipeline of boron medicines for BNCT. Once approved, the company will generate revenue from sales of its boron medicines to medical centers administering BNCT treatments. BNCT has been approved in Japan (Steboronine for head and neck cancer) and Aviko aims to bring BNCT medicines to the U.S. market.
2. Licensing and Partnership Revenue: Aviko may generate revenue through licensing agreements with pharmaceutical partners, academic medical centers, and healthcare investors to advance BNCT therapeutics and expand access to this modality.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Aviko Radiopharmaceuticals is developing a pipeline of novel boron medicines administered intravenously for use in Boron Neutron Capture Therapy (BNCT), a precision radiotherapy approach for solid tumors. The boron compounds are designed to preferentially accumulate in cancer cells and release targeted alpha particles when irradiated with low-energy neutrons, selectively destroying tumors while sparing healthy tissue. Aviko is building the broader treatment ecosystem through partnerships with neutron source and patient positioning technology providers.

Product overview

Aviko Radiopharmaceuticals is a biotechnology company developing a pipeline of boron medicines for use in Boron Neutron Capture Therapy (BNCT), an emerging precision medicine modality for treating solid tumors. Aviko's boron compounds are designed to be administered intravenously, preferentially accumulate in cancer cells, and when irradiated with safe low-energy neutrons, release alpha particles that selectively destroy tumors. The company operates as part of a broader BNCT ecosystem, partnering with Neutron Therapeutics (whose nuBeam accelerator-based neutron system provides the neutron source) and Leo Cancer Care (whose upright patient positioning system integrates with the nuBeam platform). The three companies together form a complete BNCT treatment solution comprising boron medicines, neutron delivery hardware, and patient positioning technology.

Differentiator

Problem solved

Functional benefit

Products and services

• Boron Medicines (Pipeline) Aviko's pipeline of innovative boron medicines administered intravenously and designed to selectively accumulate in tumor cells. When irradiated with safe, low-energy neutrons at the tumor site, the boron releases alpha particles that selectively destroy cancer cells while sparing healthy tissue. Intended for use at medical centers offering BNCT treatment.
• BNCT Treatment Ecosystem (with Neutron Therapeutics and Leo Cancer Care) An integrated BNCT treatment ecosystem combining Aviko's boron medicines with Neutron Therapeutics' nuBeam accelerator-based neutron delivery system and Leo Cancer Care's upright patient positioning technology. Together the three offerings form a complete BNCT treatment solution for medical centers.

Quantifiable outcome

• 71% overall response rate in recurrent/advanced head and neck cancer patients
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Leo Cancer CarecoreTechnology or Integration · 2 October 2023Exclusive strategic partnership to expand BNCT development for treating cancer. Leo Cancer Care's upright patient positioning system will be integrated into Neutron Therapeutics' nuBeam therapy platform. The partnership aims to increase versatility and impact of BNCT for patients, physicians, treatment centers, and the healthcare system through improved patient positioning for precise neutron delivery.
• Neutron TherapeuticscoreTechnology or Integration · 8 June 2023Strategic partnership to advance BNCT to treat cancer. The partnership aligns companies' efforts to build the first BNCT treatment center in the United States and establish additional BNCT facilities through collaborations with premier academic medical centers. Neutron Therapeutics provides the nuBeam accelerator-based neutron system, while Aviko provides boron medicines. Neutron has installed its nuBeam system at Helsinki University Hospital in Finland and at Shonan Kamakura General Hospital in Japan.
• Academic Medical CenterscoreStrategic or Co-development PartnerAviko is building partnerships with leading medical centers to provide BNCT care to patients. The company is working with academic medical centers to establish BNCT treatment facilities in the U.S. through collaborative arrangements.
• Biopharmaceutical CompaniessupportingStrategic or Co-development PartnerAviko partners with chemists, biologists, and other biopharma companies to develop next-generation BNCT medicines. The company seeks to expand the ecosystem of BNCT drug development through collaborative partnerships.

Scale indicators5 records

Expansion highlights6 records

Broad incumbents

• Lantheus Holdings: Specialty radiopharmaceutical company focused on diagnostic imaging agents (e.g., PYLARIFY for prostate cancer). Comparable as a broader radiopharmaceutical company operating in the radiation-based oncology space.
• Bayer (Xofigo): Developer of Xofigo (radium-223), a therapeutic radiopharmaceutical for metastatic prostate cancer. Comparable as a broad incumbent in therapeutic radiation oncology.
• Curium Pharma: Global nuclear medicine company providing diagnostic and therapeutic radiopharmaceuticals across multiple indications. Comparable as a broad incumbent in the radiopharmaceutical industry.
• Novartis (Pluvicto/Lutathera): Leader in therapeutic radiopharmaceuticals (radioligand therapy) with Pluvicto and Lutathera. Comparable as a broad incumbent in targeted radiation-based oncology therapeutics, though Aviko's BNCT is a different modality.
• Sumitomo Heavy Industries: Industrial conglomerate that built and deployed BNCT treatment systems in Japan, including at Hokkaido University and other sites. Comparable as an established BNCT infrastructure provider in the same ecosystem.

Emerging players

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents for oncology. Comparable emerging player in the targeted radiation oncology space with overlapping end users (academic medical centers).
• Perspective Therapeutics: Clinical-stage company focused on targeted alpha-particle therapeutics for cancer. Comparable as an emerging player in therapeutic radiation oncology using a different (radioligand) delivery mechanism.

Direct peers

• Neutron Therapeutics: Aviko's strategic partner developing the nuBeam accelerator-based neutron source for BNCT. Operates in the same BNCT ecosystem as a hardware/technology developer and potential competitor.
• TAE Life Sciences: Direct BNCT competitor developing accelerator-based neutron source systems and boron drugs for cancer treatment. Closest parallel to Aviko with overlapping technology and target indications.
• Stella Pharma: Japanese pharmaceutical company that developed Steboronine (boronophenylalanine), the BNCT drug approved in Japan in 2020. Directly comparable as a boron drug developer targeting the same therapeutic modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/avikobnct
• LinkedInlinkedin.com/company/avikobnct

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aviko Radiopharmaceuticals